OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - VERTEX PHARMACEUTICALS | Delayed Deutsche Boerse AG 05:07:53 2024-05-23 EDT | ||
| 25.55 EUR | -0.04% |
|
| Current month | +20.91% | ||
| 1 month | +16.66% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 25.55 | -0.04% |
| 24-05-22 | 25.56 | +2.16% |
| 24-05-21 | 25.02 | -1.81% |
| 24-05-20 | 25.48 | +0.63% |
| 24-05-17 | 25.32 | +1.61% |
Delayed Quote Deutsche Boerse AG
Last update May 23, 2024 at 05:07 am
More quotesStatic data
| Product type | Warrant Knock-Out con Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SF7UWG |
| ISIN | DE000SF7UWG6 |
| Date issued | 2021-08-18 |
| Strike | 169.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.22 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 26.03 € |
|---|---|
| Lowest since issue | 3.21 € |
| Spread | 0.27 € |
| Spread % | 1.05% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
447.5
USD
Average target price
462.8
USD
Spread / Average Target
+3.41%
- Stock Market
- Certificates
- Certificat
